Michael Aberman, MD, MBA is an Adjunct Partner for IndieBio New York. He recruits companies, identifies mentors, and actively advises founders throughout the accelerator program. Michael was the CEO & President of Quentis Therapeutics, a venture-backed oncology company. He previously served over 7 years as Senior Vice President of Strategy and Investor Relations at Regeneron. He also currently serves as Executive in Residence at Columbia Technology Ventures. He started his career at an immuno-oncology focused bio-tech startup, and then worked on Wall Street at Morgan Stanley and Credit Suisse conducting biotech equity research. Michael has a medical degree from the University of Toronto and an M.B.A. from the Wharton School of Business.

Loren Busby, CFA, MBA, is President of Cresco Advisors where she serves as an Entrepreneur in Residence and business advisor to portfolio companies. She currently works with several technology businesses operating at the intersection of artificial intelligence and healthcare as well as life science tools companies. She is also a co-founder of Life Science Vendor Expo, a conference series providing entrepreneurs with educational workshops that address some of their operating challenges. She has over two decades of experience in VC and was “one of the 6%,” referring to the exclusive group of female investment professionals. She was a Partner at NGN Capital, a transatlantic, healthcare fund where she invested in healthcare IT companies and participated in deals in the therapeutics and medical device sectors. Ms. Busby joined NGN Capital from Walden Capital Partners, which invested in the technology, manufacturing and distribution industries. In the mid-1990s, Ms. Busby worked at Princeton University’s endowment on its alternative asset portfolio. She began her career at Venture Economics and Thomson Financial, which at the time published the venerable Venture Capital Journal. From 2005-2009, Ms. Busby was a leader of CFA Society of New York’s Alternative Investments Committee, which had 450 members. She is a Chartered Financial Analyst and also earned an M.B.A. from Columbia University as a McCain Scholar and a B.S. from Central Connecticut State University.

Yaron David is a mechanical and a biomedical engineer by training. He has over ten years of experience leading teams and projects from early concept design to finalized product in the fields of opto-mechanics and medical devices both in Israel and in the US. Throughout, developed problem solving skills, expertise and commitment that are fundamental for the successful completion of any project.

Suman Lal, MD, PhD, MBA, most recently served as the cofounder and CEO of Deck Therapeutics, a company developing treatments for stroke. Dr. Suman Lal has an MD in clinical medicine, MSc in human genetics, and completed his PhD on personalizing chemotherapy regimens in breast cancer patients based on their genetic constitution. He attended MIT as a Sloan Fellow, receiving his MBA with a focus on innovation and global leadership. Dr. Lal's interests and expertise is in technology commercialization, working closely with inventors and scientists to develop early-stage ideas into 'investment ready' opportunities, and has previously co-founded companies in the areas of food & nutrition, digital health (preventive cardiology) and cosmetics.

Former Entrepreneurs in Residence

Michael B. Laskoff is a former Entrepreneur in Residence and Founder & CEO, AbleTo (acquired by UnitedHealth). Michael Laskoff is an experienced telehealth entrepreneur, executive and advisor focused on combining emerging technology and business model innovation to commercialize and scale behavioral and population healthcare solutions. Over the past decade, he has raised over $30M from highly regarded venture funds – including .406 Ventures, Sandbox/BCBS Ventures, HLM, Canaan Partners and AXA Strategic Ventures – to start and grow two, technology-enabled healthcare services companies, Annum Health and AbleTo. Currently, Michael serves on the board at Wellth (medication adherence), and an advisor to numerous healthcare startups, including: Medorion (population health AI), Intellihealth (medical treatment of obesity), Caretribe (caregiver software platform) and Equip BH (eating disorder care). He also served on the board of The Visiting Nurse Service of New York for five years. Prior to his entrepreneurial career, he worked at Furman Selz (investment banking), Bertelsmann's music division, and McKinsey & Co. Michael wrote Landing on the right Side of Your Ass, A Survival Guide for the Recently Unemployed (Three Rivers Press / Random House) and served as the "Hiring Line" columnist for BusinessWeek. He has a BA in political science from University of Chicago and an MBA from Harvard Business School. He lives with his wife in New York.

Ron Lennox is a former Entrepreneur in Residence and active investor and entrepreneur in early stage life science companies for over twenty-five years. He has served on the boards of over eighteen companies including General Surgical Innovations, Inc (acquired by Tyco International Corp), GeneOhm Sciences, Inc. (acquired by Becton Dickinson and Co.) and Applied Molecular Evolution, Inc. (acquired by Eli Lilly Corp.). He has been involved in the founding of seven companies, six of which were successful. He was founding CEO of Protometrix, Inc. (acquired by Life Technologies, Inc.), and also of CGI Pharmaceuticals, Inc. (acquired by Gilead Sciences, Inc.). He was founding Chairman of Amicus Therapeutics, Inc. (NASDAQ: FOLD). He was a founder and served as Executive Chairman of Bikam Pharmaceuticals, Inc., engineering the sale of the company to Shire Pharmaceuticals PLC in 2014. He also helped found polyGenomics, Inc., American Renal Associates, Inc., and Biorelix, Inc. Eleven additional companies he led investments in had successful IPOs including i-STAT Corp, Cephalon, Inc., British Biotechnology, Ltd., and Threshold Pharmaceuticals, Inc. Ron began his venture capital career with Hancock Venture Partners (now Harbourvest Partners). He was a founding partner at CHL Medical Partners which raised three successive funds from institutional investors. He is an Entrepreneur in Residence with Yale University's Office of Co-operative Research and Mount Sinai Innovation Partners. In addition to his role at Thetis, he is a director of RadImmune Pharmaceuticals, Inc. Ron holds a B.Sc. in Molecular Biology from the University of Glasgow, a D.Phil in Cell Biology from Oxford University and an MBA from The Wharton School of the University of Pennsylvania.

David Liu is a former Entrepreneur in Residence and currently the CEO of Sonde Health. He is a business leader who has successfully launched, led and scaled companies and products in the consumer internet, education and healthcare technology industries. David most recently served as president and chief operating officer at Quartet, helping to scale it into a leading healthcare technology company that connects primary care physicians with mental health providers to improve overall health outcomes for patients. Before Quartet, David was president and chief operating officer at Knewton, where - from an early stage - he helped to build a leading global education technology company that uses machine learning to create personalized digital textbooks that improve student learning outcomes. David began his technology career with a decade at AOL Inc., where he was senior vice president and general manager leading multiple product areas, including instant messaging, and launched the original AOL.com portal as an internal start-up. David began his career as an automotive engineer for General Motors. David received a BS in Industrial Engineering from Purdue University and an MBA from Columbia Business School.